Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Introduction: Alzheimer’s disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N -methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. Methods: We examined Clinicaltrials.gov, a public website that records ongoing clinical trials. We examined the decade of 2002 to 2012, to better understand AD-drug development. We reviewed trials by sponsor, sites, drug mechanism of action, duration, number of patients required, and rate of success in terms of advancement from one phase to the next. We also reviewed the current AD therapy pipeline. Results: During the 2002 to 2012 observation period, 413 AD trials were performed: 124 Phase 1 trials, 206 Phase 2 trials, and 83 Phase 3 trials. Seventy-eight percent were sponsored by pharmaceutical companies. The United States of America (U.S.) remains the single world region with the greatest number of trials; cumulatively, more non-U.S. than U.S. trials are performed. The largest number of registered trials addressed symptomatic agents aimed at improving cognition (36.6%), followed by trials of disease-modifying small molecules (35.1%) and trials of disease-modifying immunotherapies (18%). The mean length of trials increases from Phase 2 to Phase 3, and the number of participants in trials increases between Phase 2 and Phase 3. Trials of disease-modifying agents are larger and longer than those for symptomatic agents. A very high attrition rate was found, with an overall success rate during the 2002 to 2012 period of 0.4% (99.6% failure). Conclusions: The Clinicaltrials.gov database demonstrates that relatively few clinical trials are undertaken for AD therapeutics, considering the magnitude of the problem. The success rate for advancing from one phase to another is low, and the number of compounds progressing to regulatory review is among the lowest found in any therapeutic area. The AD drug-development ecosystem requires support.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the very high failure rate of clinical trials of AD therapeutics (of ~99.6%), many of which were successful in preclinical testing using these animal models [6, 27, 139]”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New AD drug development has faced many obstacles, including high monetary and time costs and high failure rates in preclinical and clinical trials (Cummings et al., 2014;Yiannopoulou et al., 2019).”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Cummings et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently approved drugs do little to limit disease progression, and no preventive therapies are available.3,4”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“the success rate of drugs that have gone through clinical trials from 2002 to 2012 show a high failure rate (~ 99.6%) [69]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“Efforts to develop drugs to treat Alzheimer’s dementia (AD) have a >99% failure rate”
From Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature (2021) · cites this paper as Cummings et al. 2014
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
Background2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
Clinical development success rates for investigational drugs
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2786 · Cited by 2,536 · cited 1×
“This is among the lowest for any therapeutic area [13,14].”
BackgroundThe International Committee of Medical Journal Editors
van der Weyden, M. (2006) · Proceedings of the Workshop on Publishing for Biomedical Journal Editors and Reviewers · doi:10.2349/biij.2.4.e54-13 · Cited by 1,998
Monetary Costs of Dementia in the United States
Hurd, M. D., Martorell, P., Delavande, A., Mullen, K. J., & Langa, K. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1204629 · Cited by 1,484 · cited 1×
“economy than cardiovascular disease or cancer [31].”
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · cited 1×
“2014 receptor AD antagonist (memantine) [3,4].”
Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review
Reitz, C. (2012) · International Journal of Alzheimer's Disease · doi:10.1155/2012/369808 · Cited by 376 · cited 1×
“neurobiology of AD, and use of combinations of therapies may provide new approaches to AD therapy [24-26].”
BackgroundMullane, K., & Williams, M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 213 · cited 1×
“Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a drug/placebo difference or having unacceptable toxicity [5-8].”
Background
Research works printed but not linked: 4
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2002, Bethesda, MD: US Department of Health and Human Services, Food and Drug Administration
- Food and Drug Administration: Guidance for Industry: Information Program on Clinical Trials for Serious or Life-threatening Disease and Conditions. 2004, Bethesda: US Department of Health and Human Services, Food and Drug Administration
- Getz K, Lamberti MJ: 89% of trials meet enrollment, but timelines slip, half of sites under-enroll. Tufts Cent Study Drug Dev. 2013, 15: 1-4.
- DiMasi JA: Clinical success rates for new cancer drugs double while more enter testing. Tufts Center Study Drug Dev Impact Rep. 2013, 15: 1-4.
Cited by
Items 701–800 of 1,003
Knopp, R. C., Lee, S., Hollas, M. A. R., Nepomuceno, E., González, D., Tam, K. A., Aamir, D., Wang, Y., Pierce, E. N., BenAissa, M., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101486 · Cited by 29
A systems biology approach for studying neurodegenerative diseases
Lam, S. C. C., Bayraktar, A., Zhang, C., Türkez, H., Nielsen, J., Borén, J., Shoaie, S., Uhlén, M., & Mardinoğlu, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.05.010 · Cited by 28
Simpson, L. W., Szeto, G. L., Boukari, H., Good, T. A., & Leach, J. B. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.05.030 · Cited by 25
Spitzer, P., Walter, M., Göth, C., Oberstein, T. J., Linning, P., Knölker, H., Kornhuber, J., & Maler, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01967 · Cited by 28
Hithersay, R., Baksh, R. A., Startin, C. M., Wijeratne, P. A., Hamburg, S., Carter, B., & Strydom, A. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12222 · Cited by 27
Gallego, I., Villate-Beitia, I., del Burgo, L. S., Puras, G., & Pedraz, J. L. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000418 · Cited by 33
“In particular, CNS ECs are held together by tight junctions (Kniesel and Wolburg, 2000; Luissint et al., 2012a) regulating the homeostatic movement of ions, molecules, and cells between the blood and the CNS (Daneman and Prat, 2015; Serlin et al., 2015) (Fig.”
BackgroundDelbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 28
Javed, H., Fizur, N. M. M., Jha, N. K., Ashraf, G. M., & Ojha, S. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221223120251 · Cited by 208
“Due to limited research and knowledge about neurological diseases, the drug development process is very slow; the FDA has not approved any new drug for AD since 2003 [26].”
BackgroundPolyoxidovanadates a new therapeutic alternative for neurodegenerative and aging diseases
González‐Cano, S. I., Flores, G., Guevara, J., Morales‐Medina, J. C., Treviño, S., & Díaz, A. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380877 · Cited by 27
“Additionally, clinical trials on AD have been relatively scarce in recent years, presenting a 99.6% failure rate (Cummings et al., 2014).”
BackgroundInfluentialSystematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease
Hernandez, L. G., Ozen, A., DosSantos, R., & Getsios, D. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0392-1 · Cited by 26
“Inevitably, including patients at the early stages of AD and modeling the potential impact of DMTs on survival will increase the complexity and data demands of future models of AD.”
InfluentialSnyder, H. M., Shineman, D. W., Friedman, L. G., Hendrix, J. A., Khachaturian, A. S., Guillou, I. L., Pickett, J., Refolo, L. M., Sancho, R. M., & Ridley, S. H. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.07.001 · Cited by 28
Borelli, W. V., Schilling, L. P., Radaelli, G., Ferreira, L. B., Pisani, L., Portuguez, M. W., & da Costa, J. C. (2018) · International Psychogeriatrics · doi:10.1017/s1041610218000431 · Cited by 29
“First published online 18 April 2018. disease (AD) have not provided promising results (Cummings et al., 2014), different therapeutic targets must be investigated.”
BackgroundA blood-based signature of cerebrospinal fluid Aβ1–42 status
Goudey, B., Fung, B. J., Schieber, C., Faux, N. G., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37149-7 · Cited by 25
Variation across Species and Levels: Implications for Model Species Research
Striedter, G. F. (2019) · Brain Behavior and Evolution · doi:10.1159/000499664 · Cited by 30
“Increasingly, the answer is “probably not,” especially in light of the fact that the vast majority of therapies developed in model species has failed in clinical trials, especially for therapies aimed at neurological disorders [Cummings et al., 2014; Petrov et al., 2017].”
BackgroundMishra, C. B., Gusain, S., Shalini, S., Kumari, S., Prakash, A., Kumari, N., Yadav, A. K., Kumari, J., Kumar, K., & Tiwari, M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103524 · Cited by 30
Pistollato, F., Bernasconi, C., McCarthy, J., Campia, I., Desaintes, C., Wittwehr, C., Deceuninck, P., & Whelan, M. (2020) · Animals · doi:10.3390/ani10071194 · Cited by 27
“With regard to AD, the failure rate of drug development reaches 99% [23], and zero disease-modifying therapies have been developed so far [24].”
BackgroundSimone, A. D., Bartolini, M., Baschieri, A., Apperley, K. Y.-P., Chen, H. H., Guardigni, M., Montanari, S., Kobrlová, T., Soukup, O., Valgimigli, L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.058 · Cited by 26
Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
“4% between 2002 and 2012; one of the poorest success rates of any disease (Cummings et al., 2014).”
BackgroundInfluentialIntracerebral Nanoparticle Transport Facilitated by Alzheimer Pathology and Age
Tracy, G. C., Huang, K.-Y., Hong, Y.-T., Ding, S., Noblet, H. A., Lim, K. H., Kim, E. C., Chung, H. J., & Kong, H. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03222 · Cited by 24
Boyton, I., Valenzuela, S. M., Collins‐Praino, L. E., & Care, A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.004 · Cited by 23
A Contextual-Bandit-Based Approach for Informed Decision-Making in Clinical Trials
Varatharajah, Y., & Berry, B. M. (2022) · Life · doi:10.3390/life12081277 · Cited by 28
When Neuroscience Meets Pharmacology: A Neuropharmacology Literature Analysis
Yeung, A. W. K., Tzvetkov, N. T., & Atanasov, A. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00852 · Cited by 26
“4% overall success rate of 413 clinical trials on AD conducted during 2002–2012 (Cummings et al., 2014).”
BackgroundInfluentialEndosomal Acid-Base Homeostasis in Neurodegenerative Diseases
Prasad, H., & Rao, R. (2020) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2020_25 · Cited by 26
Drabik, K., Malińska, D., Piecyk, K., Dębska–Vielhaber, G., Vielhaber, S., Duszyński, J., & Szczepanowska, J. (2021) · Antioxidants · doi:10.3390/antiox10060938 · Cited by 25
Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer’s Disease
Uliassi, E., de Oliveira, A. S., Nascente, L. D. C., Romeiro, L. A. S., & Bolognesi, M. L. (2021) · Molecules · doi:10.3390/molecules26185441 · Cited by 36
“4%, as compared with 20% for cancer [4].”
BackgroundDOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer’s Disease
Chyr, J., Gong, H., & Zhou, X. (2022) · Biomolecules · doi:10.3390/biom12020196 · Cited by 24
Sun, F., Zhao, J. J., Zhang, H., Shi, Q., Liu, Y., Robert, A., Liu, Q., & Meunier, B. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00455 · Cited by 25
Kumar, S., Manoharan, A., Jayalakshmi, J., Abdelgawad, M. A., Mahdi, W. A., Alshehri, S., Ghoneim, M. M., Pappachen, L. K., Zachariah, S. M., Aneesh, T. P., et al. (2023) · RSC Advances · doi:10.1039/d3ra00526g · Cited by 24
The elusive role of herpesviruses in Alzheimer’s disease: current evidence and future directions
Piotrowski, S. L., Tucker, A., & Jacobson, S. (2023) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2023-0011 · Cited by 24
Therapeutic Strategies Aimed at Improving Neuroplasticity in Alzheimer Disease
Colavitta, M. F., & Barrantes, F. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082052 · Cited by 25
Alkynyl and β-ketophosphonates: Selective and potent butyrylcholinesterase inhibitors
Cavallaro, V., Moglie, Y., Murray, A. P., & Radivoy, G. E. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.030 · Cited by 24
Protein and Peptides for Elderly Health
Shang, N., Chalamaiah, M., Bandara, N., & Wu, J. (2018) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.03.003 · Cited by 24
Impact evaluation of assistive technology support for the people with dementia
Asghar, I., Cang, S., & Yu, H. (2018) · Assistive Technology · doi:10.1080/10400435.2017.1411405 · Cited by 25
Neuroprotective Effects of Amylin Analogues on Alzheimer’s Disease Pathogenesis and Cognition
Grizzanti, J., Corrigan, R. R., & Casadesús, G. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180433 · Cited by 26
“Since then, a staggering amount of drug trials have failed worldwide, demonstrating our crucial need for the development of new and innovative therapies for the treatment of AD [13].”
Yu, J., Kwon, H., Cho, E., Jeon, J., Kang, R. H., Youn, K., Jun, M., Lee, Y. C., Ryu, J. H., & Kim, D. H. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.01.017 · Cited by 30
Mahalingam, S., & Chen, M.-K. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678580 · Cited by 33
The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer’s Disease
Ghosh, A. K., Cárdenas, E. L., & Osswald, H. L. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_16 · Cited by 23
“A number of approved drugs are available only to treat symptoms in AD patients [5].”
BackgroundAhnaou, A., Walsh, C., Manyakov, N. V., Youssef, S. A., & Drinkenburg, W. H. I. M. (2019) · Neural Plasticity · doi:10.1155/2019/6981268 · Cited by 27
“Until relatively recently, pharma drug discovery in the field of AD has been focused on therapies that reduce the levels of soluble or insoluble Aβ in the brain; however, numerous high-profile late-stage failures in clinical trials have resulted in a shift in focus to reducing the levels of tau in the brain far earlie…”
BackgroundThe Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy
Caobi, A., Dutta, R. K., Garbinski, L. D., Esteban-López, M., Ceyhan, Y., Andre, M., Manevski, M., Ojha, C. R., Lapierre, J., Tiwari, S., et al. (2020) · Aging and Disease · doi:10.14336/ad.2019.0927 · Cited by 28
“The current treatment for AD consists of cholinesterase inhibitors such as donepezil and the glutamate agonist memantine [69].”
BackgroundXiao, J., Savonenko, A. V., & Yolken, R. H. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104660 · Cited by 23
Hampel, H. J., Mesulam, M. M., Cuello, A. C., Khachaturian, A. S., Farlow, M. R., Snyder, P. J., Giacobini, E., & Khachaturian, Z. S. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.08.016 · Cited by 25
RetractedRao, C. V., Farooqui, M., Zhang, Y., Asch, A. S., & Yamada, H. Y. (2018) · Aging Cell · doi:10.1111/acel.12797 · Cited by 24
Prasansuklab, A., Theerasri, A., Payne, M. S., Ung, A. T., & Tencomnao, T. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2288-4 · Cited by 24
Brookmeyer, R., & Abdalla, N. (2019) · Clinical Trials · doi:10.1177/1740774518816323 · Cited by 24
“At present, only five drugs for the treatment of Alzheimer’s dementia have been approved by the Food and Drug Administration, and while they temporarily relieve symptoms, they do not stop the progressive brain damage.(2) In recent years, a number of promising drugs failed to show clinical benefit in double-blind place…”
The Paradoxical Effect of Deep Brain Stimulation on Memory
Kai, T. S. Z., Man-Lung, F., Koh, J., Ying-Shing, C., & Lim, L. W. (2020) · Aging and Disease · doi:10.14336/ad.2019.0511 · Cited by 26
“However, the treatment effects tend to diminish over time [120] and there are issues with drug toxicity, and lack of significant therapeutic effects have resulted in high failure rates [121, 122].”
BackgroundMosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimer’s Disease
Kaeser, G. E., & Chun, J. J. M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00390 · Cited by 24
“Another major criticism of the amyloid hypothesis has been its failure to yield any diseasemodifying therapies despite the many clinical trials targeting Aβ components (Carlsson, 2008; Cummings et al., 2014; Anderson et al., 2017; Mehta et al., 2017; Burki, 2018; Egan et al., 2018).”
BackgroundChen, S., Jiang, Q., Huang, P., Hu, C., Shen, H., Schachner, M., & Zhao, W. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.06.004 · Cited by 24
Tambaro, S., Galán-Acosta, L., Leppert, A., Chen, G., Biverstål, H., Presto, J., Nilsson, P., & Johansson, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004538 · Cited by 25
“The long row of failed AD clinical trials emphasizes the importance to develop new strategies that are able to counteract the onset and course of this disease (35).”
BackgroundDNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells
Xiang, J., Zhang, W., Cai, X., Cai, M., Yu, Z., Yang, F., Zhu, W., Li, X.-T., Wu, T., Zhang, J., et al. (2019) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2019.02.025 · Cited by 19
“Unfortunately, nearly all efforts to target Ab have failed so far.(3) Several clinical trials show that antibodies against Ab bring no benefit to the cognition of AD patients.”
BackgroundLanthier, C., Payan, H., Liparulo, I., Hatat, B., Lecoutey, C., Since, M., Davis, A., Bergamini, C., Claeysen, S., Dallemagne, P., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111596 · Cited by 26
Turning Donepezil into a Multi‐Target‐Directed Ligand through a Merging Strategy
Perone, R. C., Albertini, C., Uliassi, E., Pietri, F. D., Pinheiro, P. D. S. M., Petralla, S., Rizzardi, N., Fato, R., Pulkrabkova, L., Soukup, O., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000484 · Cited by 23
Kaur, A., Goyal, D., & Goyal, B. (2020) · Physical Chemistry Chemical Physics · doi:10.1039/d0cp04672h · Cited by 22
Interdisciplinary Research in Alzheimer’s Disease and the Roles International Societies Can Play
Tan, S. Z. K., Zhao, R. C., Chakrabarti, S., Stambler, I., Jin, K., & Lim, L. W. (2021) · Aging and Disease · doi:10.14336/ad.2020.0602 · Cited by 22
“A complex interplay of issues must be addressed from the need for equitable medical systems for the smaller young healthy population [6] and effective treatments and limitations of current therapies [7, 8] to the ethics of antiageing treatments [9, 10], and so on.”
BackgroundShannon, O. M., Lee, V. Y., Bundy, R., Gillings, R., Jennings, A., Stephan, B. C. M., Hornberger, M., Balanos, G. M., Paddick, S., Hanson, S., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-042823 · Cited by 23
Dai, M., Yang, X., Yu, Y., & Pan, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827486 · Cited by 28
Combination Therapy in Alzheimer’s Disease: Is It Time?
Salehipour, A., Bagheri, M., Sabahi, M., Dolatshahi, M., & Boche, D. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215680 · Cited by 22
“…therapy development only for “serious diseases,” defined as “a disease or condition associated with morbidity that has substantial impact on day-to-day functioning” [3] and has issued specific guidelines on combination therapy development for cancer, tuberculosis, and HIV infection [6, 53, 140].”
Song, J., Bang, S., Choi, N., & Kim, H. N. (2022) · Biomicrofluidics · doi:10.1063/5.0121476 · Cited by 26
Jamalian, S., Dolton, M. J., Chanu, P., Ramakrishnan, V., Franco, Y. L., Wildsmith, K. R., Manser, P. T., Teng, E., Jin, J. Y., Quartino, A. L., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12974 · Cited by 25
Schmidt-Morgenroth, I., Michaud, P., Gasparini, F., & Avraméas, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310523 · Cited by 27
Predicting targets of compounds against neurological diseases using cheminformatic methodology
Nikolic, K. M., Mavridis, L., Bautista‐Aguilera, Ó. M., Marco‐Contelles, J., Stark, H., Carreiras, M. C., Rossi, I., Massarelli, P., Agbaba, D. D., Ramsay, R. R., et al. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9816-1 · Cited by 22
“Memantine also acts as a non-competitive antagonist at the 5-HT3 receptor and binds to dopamine D2 receptors and nAChRs [43].”
BackgroundZhang, L., Chen, L. M., Dutra, J. K., Beck, E. M., Nag, S., Takano, A., Amini, N., Arakawa, R., Brodney, M. A., Buzon, L. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01769 · Cited by 25
Go with the Flow—Microfluidics Approaches for Amyloid Research
Zilberzwige‐Tal, S., & Gazit, E. (2018) · Chemistry - An Asian Journal · doi:10.1002/asia.201801007 · Cited by 33
Wang, X., Zhao, C.-P., Zhong, L.-C., Zhu, D.-L., Mai, D.-H., Liang, M.-G., & He, M. (2018) · Molecules · doi:10.3390/molecules23123100 · Cited by 22
Page, S., Patel, R., Raut, S., & Al-Ahmad, A. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.12.009 · Cited by 25
Cummings, J. L., Atri, A., Ballard, C. G., Boneva, N., Frölich, L., Molinuevo, J. L., Rakêt, L. L., & Tariot, P. N. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0443-2 · Cited by 22
Self-citationConrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21
“The approved symptomatic AD drugs are (i) the cholinesterase inhibitors: tacrine, donepezil, rivastigmine, and galantamine and (ii) the N-methyl-d-aspartate (NMDA) receptor antagonist memantine.(10) Memantine, approved in 2003, has been the most recent medication approved for use in AD.”
BackgroundNicola, L., Loo, S. J. Q., Lyon, G., Turknett, J., & Wood, T. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102356 · Cited by 25
Mezias, C., & Raj, A. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00653 · Cited by 25
Cummings, J. L. (2020) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.20060152 · Cited by 26
Self-citationDysregulated gene-associated biomarkers for Alzheimer’s disease and aging
Li, M., Geng, R., Li, C., Meng, F., Zhao, H., Liu, J., Dai, J., & Wang, X. (2021) · Translational Neuroscience · doi:10.1515/tnsci-2021-0009 · Cited by 22
“biomarkers for diagnosis and pathogenesis was one of the key reasons for the current unavailability to treat or prevent AD [3].”
BackgroundGáspár, A., Hutka, B., Ernyey, A. J., Tajti, B. T., Varga, B. T., Zádori, Z., & Gyertyán, I. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.662173 · Cited by 22
Godyń, J., Zaręba, P., Łażewska, D., Stary, D., Reiner‐Link, D., Frank, A., Latacz, G., Mogilski, S., Kaleta, M., Doroż-Płonka, A., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105129 · Cited by 21
Wang, Y., Huynh, T. T., Cho, H.-J., Wang, Y.-C., Rogers, B. E., & Mirica, L. M. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c02079 · Cited by 25
Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer’s Disease Mouse Model
Jeong, Y. J., Son, Y., Park, H.-J., Oh, S. J., Choi, J. Y., Ko, Y.-G., & Lee, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179374 · Cited by 21
“Despite compelling genetic and molecular evidence pointing to βA as a key player in AD pathogenesis [5], the majority of clinical trials targeting βA cascades have produced negative results [6,7].”
BackgroundMarkova, E., Taneska, L., Kostovska, M., Shalabalija, D., Mihailova, L., Dodov, M. G., Makreski, P., Geškovski, N., Petrushevska, M., Taravari, A. N., et al. (2022) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.35006 · Cited by 23
Exploring common genetic contributors to neuroprotection from amyloid pathology
Seto, M., Mahoney, E. R., Dumitrescu, L. C., Ramanan, V. K., Engelman, C. D., Deming, Y. K., Albert, M., Johnson, S. C., Zetterberg, H., Blennow, K., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac066 · Cited by 19
Wu, Y., Rakotoarisoa, M., Angelov, B., Deng, Y., & Angelova, A. (2022) · Nanomaterials · doi:10.3390/nano12132267 · Cited by 21
“In AD, four drugs have been used for the treatment of the dementia phase, namely, the glutamate antagonist memantine and the cholinesterase inhibitors donepezil, rivastigmine, and galantamine [24].”
BackgroundReagan, A. M., Christensen, K. E., Graham, L. C., Bedwell, A. A., Eldridge, K., Speedy, R., Figueiredo, L. L., Persohn, S. A., Bottiglieri, T., Nho, K. T., et al. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221122644 · Cited by 25
“6 Recent evidence suggests that the majority of cases of AD also present clinically with cerebrovascular complications that contribute to initiation and progression of the disease through diverse mechanisms including ischemia, vascular inflammation, blood brain barrier (BBB) dysfunction, small…”
BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR
Makani, V. S., Jang, Y.-G., Christopher, K., Judy, W., Eckstein, J. M., Hensley, K., Chiaia, N. L., Kim, D.-S., & Park, J. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149715 · Cited by 22
Cognitive ‘Omics’: Pattern-Based Validation of Potential Drug Targets
Gyertyán, I. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.010 · Cited by 21
Lee, D., Lee, G., & Yoon, D. S. (2018) · The Analyst · doi:10.1039/c7an02013a · Cited by 20
Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders
Verma, M. K., Goel, R., Krishnadas, N., & Nemmani, K. V. S. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1487952 · Cited by 21
“For AD, investigational disease-modifying therapies comprise of approximately 70% of total clinical trial underway at various phases underscoring the need for developing novel interventions [7].”
BackgroundAladeokin, A. C., Akiyama, T. H., Kimura, A., Kimura, Y., Jitsuki‐Takahashi, A., Nakamura, H., Makihara, H., Masukawa, D., Nakabayashi, J., Hirano, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104603 · Cited by 25
Liang, J., Lü, L., Wang, Y., Jia, R., Qu, X.-Y., Li, J., Li, J., Qian, S., Qian, Y., Wang, S., et al. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100965 · Cited by 25
Lee, B., Kim, M., Lee, S. Y., Son, S. J., Hong, C. H., & Jung, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061642 · Cited by 23
“shifting towards treatment at earlier stages of the disease, thus delaying the progression of MCI to AD [4].”
BackgroundDoes Alzheimer's disease stem in the gastrointestinal system?
Khodabakhsh, P., Bazrgar, M., Dargahi, L., Mohagheghi, F., Taei, A. A., Parvardeh, S., & Ahmadiani, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120088 · Cited by 23
Mukherji, D., Mukherji, M., Mukherji, N., & Initiative, A. D. N. (2022) · Brain Informatics · doi:10.1186/s40708-022-00169-1 · Cited by 27
“In spite of the scale of the problem, there is no cure for the disease and countless clinical trials have been unsuccessful in finding effective treatment [5, 8].”
BackgroundReagan, A. M., Christensen, K. E., Graham, L. C., Bedwell, A. A., Eldridge, K., Speedy, R., Figueiredo, L. L., Persohn, S. C., Bottiglieri, T., Sasner, M., et al. (2021) · doi:10.1101/2021.12.16.472805 · Cited by 21
Federated Learning Model for Early Detection of Dementia Using Blood Biosamples
Elsersy, M. S., Sherif, A., Imam, A. A.-A., Mamun, M. M. R. K., Khalil, K., & Haitham, M. (2023) · International Conference on Artificial Intelligence, Blockchain, and Internet of Things (AIBThings) · doi:10.1109/aibthings58340.2023.10292491 · Cited by 20
“Despite spending billions of dollars on research to find a cure for Alzheimer’s disease (AD), the most common form of dementia, no disease-ending treatments are available on the market at this time [3].”
BackgroundDo microbes play a role in Alzheimer's disease?
Williams, Z. A. P., Láng, L., Nicolas, S., Clarke, G. A., Cryan, J. F., Vauzour, D., & Nolan, Y. M. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.14462 · Cited by 22
“However, after over 400 clinical trials targeting brain-derived A β , such a strategy has not proven to be very effective (Banik et al., 2015; Cummings et al., 2014; Geldenhuys & Darvesh, 2015; Knopman, Jones, & Greicius, 2021).”
BackgroundArastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21
“last symptomatic AD drug was approved by the United States Food and Drug Administration (FDA), truly highlights the sense of frustration of this research area [3,4].”
BackgroundFrom Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases
Zhu, Y., Xu, P., Huang, X., Wen, S., Liu, L., Zhang, S., Zhao, R., Hu, X., & Wang, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.920113 · Cited by 23
Cui, W.-B., Zhang, Z., Bai, X., Wang, S., Chen, X., Liu, X., Su, P., Zhi, D., Fei, D., Zhang, Z., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710030 · Cited by 22
Liu, W., Li, Y., Xu, L., & Jia, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03032-w · Cited by 20
Multiple Actions of H2S-Releasing Peptides in Human β-Amyloid Expressing C. elegans
Ali, R., Hameed, R., Chauhan, D., Sen, S., Wahajuddin, M., Nazir, A., & Verma, S. K. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00402 · Cited by 21
Wu, Y., Xu, D., He, Y., Yan, Z., Liu, R., Liu, Z., He, C., Liu, X., Yu, Y., Yang, X., et al. (2023) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0011350 · Cited by 22
“However, few effective drugs are currently available for treatment [3].”
BackgroundTin, A., Fohner, A. E., Yang, Q., Brody, J. A., Davies, G., Yao, J., Liu, D., Caro, I., Lindbohm, J. V., Duggan, M. R., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05454-1 · Cited by 22
“No treatment exists for curing dementia, some clinical trials are thought to have failed because the intervention was too late in the pathologic process 2 .”
Mitochondrial Targeting against Alzheimer’s Disease: Lessons from Hibernation
Mestdagh, C. F. D. V., Smit, A. B., Henning, R. H., & van Kesteren, R. E. (2023) · Cells · doi:10.3390/cells13010012 · Cited by 23
“Previous experience has taught that translating therapeutic strategies that show promising effects in AD mouse models to human treatment is often unsuccessful [149,150].”
BackgroundAbulafia, C., Duarte-Abritta, B., Villarreal, M. F., Ladrón-de-Guevara, M. S., García, C., Sequeyra, G., Sevlever, G. E., Fiorentini, L., Bär, K., Gustafson, D., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00093 · Cited by 21
Özdemir, Z., Yılmaz, H., Sarı, S., Karakurt, A., Şenol, F. S., & Uysal, M. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1930-x · Cited by 22
“1) have been used contemporarily for the symptomatic treatment of AD (Mehta et al. 2012; Zha et al. 2016; Williams et al. 2011; Cummings et al. 2007; Costanzo et al. 2016; Romero et al. 2013; Camps et al. 2008).”
Method
Metadata
- Authors
- Cummings, J. L., Morstorf, T., & Zhong, K.
- Affiliations
- Cleveland Clinic (US)
- Touro University Nevada (US)
- Corresponding author
- Cummings, Jeffrey L
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 4
- Pages
- 37-37
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4095696
- OpenAlex
- W2146249493
- Cited by
- 1,744
- References
- 29
- Citations by year
- 2026: 86 · 2025: 65 · 2024: 113 · 2023: 122 · 2022: 189 · 2021: 193 · 2020: 208 · 2019: 207 · 2018: 200 · 2017: 144 · 2016: 122 · 2015: 79 · 2014: 15
- FWCI
- 79.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, drug development pipeline, clinical trials, trial attrition, disease-modifying therapy, immunotherapy, cholinesterase inhibitors, NMDA receptor antagonists, ClinicalTrials.gov, pharmaceutical industry sponsorship
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
